Full Issue

Individual Articles - Nov/Dec 2019 - Volume 23, Number 6

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Nov/Dec 2019 Pg. 444	PreScription: As Things Change…. Author(s): Allen Loyd V Jr
Nov/Dec 2019 Pg. 447-452	Primary Engineering Controls in Pharmaceutical Compounding, Part 1: Unidirectional-airflow Workstations, Compounding Aseptic Isolators, and Compounding Aseptic Containment Isolators Author(s): Mulder Kyle
Nov/Dec 2019 Pg. 454-461	How to Qualify Container Closure Systems for Intended Use, Part 1 Author(s): Kim Amy A, Gehrmann Matthew R, McCaw James, McAndrew T Page
Nov/Dec 2019 Pg. 462-464	Are You Part of the Solution or Part of the Problem? Author(s): Brunner Scott
Nov/Dec 2019 Pg. 467-471	Quality Control: Hand and Glove Sanitizing in Sterile Compounding, Part 2 Author(s): Greeson Nicole MH, Mixon William, Huslage Kirk, Stiegel Matthew A, Thomann Wayne R
Nov/Dec 2019 Pg. 472-477	Basics: Excipients Used in Nonsterile Compounding, Part 3: Preservatives Author(s): Allen Loyd V Jr
Nov/Dec 2019 Pg. 478-482	Intravenous Admixture Preparation Considerations, Part 1: Overview of Series on Personnel Selection for Intravenous Admixture Compounding Author(s): Allen Loyd V Jr
Nov/Dec 2019 Pg. 484	Calculations Author(s): Stockton Shelly J, Stover Emily M
Nov/Dec 2019 Pg. 486	Gabapentin 50-mg/mL in SyrSpend SF Oral Suspension Author(s): Allen Loyd V Jr
Nov/Dec 2019 Pg. 487	Prednisolone Sodium Phosphate 1.4 mg/mL in SyrSpend SR pH4, Cherry Flavored Author(s): Allen Loyd V Jr
Nov/Dec 2019 Pg. 488	Pregabaline 20 mg/mL in SyrSpend SR pH4 Oral Suspension Author(s): Allen Loyd V Jr
Nov/Dec 2019 Pg. 489	Riboflavin 10 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Nov/Dec 2019 Pg. 490	Sulfasalazine 100 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Nov/Dec 2019 Pg. 491	Tacrolimus Monohydrate 1 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Nov/Dec 2019 Pg. 492	Tadalafil 5 mg/mL in Oral-Plus:Ora-Sweet (1:1) Author(s): Allen Loyd V Jr
Nov/Dec 2019 Pg. 493	Ursodiol 30 mg/mL in SyrSpend SF Cherry Oral Suspension Author(s): Allen Loyd V Jr
Nov/Dec 2019 Pg. 494	Verapmail Hydrochloride 50 mg/mL in SyrSpend SF Author(s): Allen Loyd V Jr
Nov/Dec 2019 Pg. 495	Zonisamide 10 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Nov/Dec 2019 Pg. 496-503	Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy? Author(s): Shakshuki Ayah, Agu Remigius U
Nov/Dec 2019 Pg. 504-510	Compatibility of Flavoring Agents in Compounding Extemporaneous Omeprazole Oral Liquid Author(s): Chuong Monica, Taglieri Catherine A, Huang Szu Yu, Sariol Anthony, Kitigawa Reina, Barman Koushik, Mistry Amee, Harris Donna L, Kerr Stephen G
Nov/Dec 2019 Pg. 511-518	Evaluation of Containment Ventilated Enclosure Performance in Absence of Negative Pressure Containment Secondary Engineering Control Author(s): Hutson Chad, Day A J
Nov/Dec 2019 Pg. 519-527	Physicochemical Stability of Compounded Amlodipine Besylate Suspensions in PCCA Base, SuspendIt Author(s): Graves Richard A, Mandal Tarun K, Bostanian Levon A, Nguyen Anh TQ, Swopes Demikka, Morris Tommy C, Pramar Yashoda V